The Zacks Analyst Blog Highlights: Theravance, Astellas Pharma, Hospira, GlaxoSmithKline and Winthrop Realty Trust
For Immediate Release
Chicago, IL – August 16, 2013 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Theravance, Inc. (THRX-FreeReport), Astellas Pharma (ALPMY-Free Report), Hospira, Inc. (HSP-Free Report), GlaxoSmithKline (GSK-Free Report) and Winthrop Realty Trust (FUR-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday’s Analyst Blog:
Good News for Theravance
We note that the drug is also approved for treating adults suffering from hospital-acquired and ventilator-associated bacterial pneumonia when other alternatives are not available. We note that Theravance’s deal with Astellas Pharma (ALPMY-Free Report) regarding Vibativ was terminated by the latter in Jan 2012. Following the termination of the deal, supplies of Vibativ were hit badly, leading to the suspension of commercialization of the antibiotic. To resolve the situation, Theravance inked a supply deal for Vibativ with Hospira, Inc. (HSP-Free Report). In Jun 2013, the U.S. Food and Drug Administration (:FDA) approved Hospira as a manufacturer of Vibativ.
With Vibativ supplies being restored, Theravance resumed shipping the drug into the U.S. wholesaler channel. The reintroduction of Vibativ in the U.S. is very encouraging for Theravance as the resumption of sales would bring in additional revenues to the company.
We are also positive on Theravance’s partnership with GlaxoSmithKline (GSK-Free Report). In May 2013, Theravance received a boost when the FDA approved Breo Ellipta, also co-developed with Glaxo, as a long-term maintenance therapy of airflow obstruction and for bringing down exacerbations in patients suffering from COPD. Breo Ellipta is expected to be available from the third/fourth quarter of 2013. Another COPD candidate, developed under this partnership, is Anoro Ellipta. The candidate is under review in the U.S. (target date: Dec 18, 2013).
Theravance carries a Zacks Rank #3 (Hold). Hospira appears to be more attractive with a Zacks Rank #2 (Buy).
Winthrop to Buy 4 Apartment Assets
Mass.-based real estate investment trust (:REIT), Winthrop Realty Trust (FUR-Free Report) inked a binding purchase deal to acquire 4 recently built Class A luxury apartment assets – 44 Monroe, Highgrove, Mosaic II and San Pedro Lofts – for about $246 million. The move was in line with the company’s strategy of buying high quality condo constructed multifamily assets.
44 Monroe is a 34-story residential property (184 units) in Arizona, Phoenix and Highgrove is an 18-story residential building (92 units) in Stamford, Conn. Moreover, Mosaic II is a 29-story residential property (396 units) in Houston, Texas and San Pedro Lofts comprises 2 distinct residential buildings (89 units) in San Pedro, Calif.
Winthrop expects the acquisition of these properties to close around September to October this year, subject to customary closing conditions. For buying the assets, the company provided a non-refundable deposit worth $25.5 million. The balance amount is anticipated to stem from a mix of available cash and new secured financing.
Notably, Winthrop is focused on riding the growth trajectory by capitalizing on opportunistic investments and the current deal is a part of such efforts. We expect the above-mentioned accretive acquisitions to enhance its portfolio quality and drive bottom-line growth.
Winthrop Realty engages in the ownership and management of real estate and real estate-related financial instruments such as CMBS, bonds, REIT preferred and common stock. The company carries a short-term Zacks Rank #1 (Strong Buy).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on THRX - FREE
Get the full Report on ALPMY - FREE
Get the full Report on HSP - FREE
Get the full Report on GSK - FREE
Get the full Report on FUR - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Read the analyst report on THRX
Read the analyst report on ALPMY
Read the analyst report on HSP
Read the analyst report on GSK
Read the analyst report on FUR
More From Zacks.com
